Perceptive Informatics today announced that it has selected TIBCO Software Inc. (NASDAQ: TIBX) to enhance its suite of eClinical service offerings, incorporating enterprise infrastructure software, TIBCO ActiveMatrix BusinessWorks™, as well as TIBCO Enterprise Message Service™, into its eClinical platform. The TIBCO solution provides integration of software applications and real-time data exchange capabilities across Perceptive’s eClinical Suite to help its customers make more effective decisions about their clinical development programs.
The new capabilities bring further performance improvements to Perceptive’s eClinical platform including reporting, integration, and identity management solutions, which enable applications of its eClinical Suite. The TIBCO solution will enable Perceptive to provide its customers with improved application integration efficiency, with greater standardization and reduced implementation timeframes.
TIBCO ActiveMatrix BusinessWorks™ brings enhanced capabilities to Perceptive’s common framework for integrating and synchronizing systems and web-based services. In combining TIBCO’s orchestration and integration technologies with its extensive experience, Perceptive is delivering hundreds of solutions integrations for its customers to help improve data quality, streamline workflow, and enable a fully standardized integration process.
The eClinical Suite from Perceptive Informatics provides advanced integration and interoperability among systems, including the IMPACT® Clinical Trial Management System (CTMS), the Medical Imaging tracking application, the DataLabs® EDC solution, and the ClinPhone® Randomization and Trial Supply Management (RTSM) technologies. The Suite supports real-time data interchange and enables diverse applications to work synergistically. For more information about Perceptive’s eClinical Suite visit: http://www.perceptive.com/Solutions/eClinical-Suite.html.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.